TransgeneFRA:TGNA -0.28%44 FCF Yield % is -18.03 as of Jul. 04, 2026. GuruFocus rates FRA:TGNA with a GF Score™ of 44/100 and a GF Value™ of €0.48 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,413 Biotechnology companies, Transgene ranks worse than 65.32% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Transgene FCF Yield % Related Terms
Transgene FCF Yield % Historical Data
* Premium members only.
The historical data trend for Transgene's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TGNA vs VRTX, REGN, ALNY: FCF Yield % Comparison
For the Biotechnology subindustry, Transgene's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Transgene FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Transgene's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Transgene's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Transgene (FRA:TGNA) has a FCF Yield % of -18.03 as of Jul. 04, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Transgene and its competitors. According to the industry distribution chart, Transgene ranks #923 out of 1413 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Transgene's FCF Yield % too high?
Transgene's current FCF Yield % is -18.03. Based on the distribution chart, Transgene ranks #923 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Transgene has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transgene's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene ranks #923 out of 1413 companies for FCF Yield %. This places Transgene in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Transgene and its competitors. Transgene's current FCF Yield % is -18.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene stock overvalued right now?
Based on GuruFocus' analysis, Transgene (FRA:TGNA) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.48, compared to a current price of €0.70 — trading 45.8% above its estimated fair value. The current FCF Yield % is -18.03. Transgene's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Transgene (FRA:TGNA), the current FCF Yield % is -18.03 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Transgene (FRA:TGNA) Overvalued in 2026?
Based on GuruFocus' analysis, Transgene stock appears to be overvalued.
The current stock price of €0.70 is trading 45.8% above its estimated GF Value™ of €0.48.
GuruFocus considers Transgene to be Significantly Overvalued.
Key valuation signals for FRA:TGNA:
FCF Yield %: -18.03
GF Value™: €0.48 vs. price of €0.70 (45.8% above fair value)
No single metric tells the full story. See the FRA:TGNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Transgene SA is a biotechnology company that designs and develops virus based immunotherapy products focused on the development of individualized therapeutic vaccines against cancers. The flagship program, TG4050, is an individualized therapeutic vaccine based on the myvac platform. The company also has other viral vector-based programs, including BT-001, an oncolytic virus based on the Invir.IO viral backbone, which is in clinical development. In addition, it conducts discovery and preclinical work, aimed at developing novel immunotherapies.
44GF Score
Get the complete analysis for FRA:TGNA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TGNA has been successfully added to your 
